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Abstract: TCR gene therapy represents a feasible and promising treatment for patients with cancer and virus infections. 
Currently, this treatment rationale is hampered by diluted surface expression of the TCR transgene and generation of  
potentially self reactive T-cells, both a direct consequence of mis-pairing with endogenous TCR chains. As we reported 
previously (Gene Ther 16:1369, 2000; J Immunol 180:7736, 2008), TCR mis-pairing can be successfully addressed by a 
TCR:CD3 fusion protein (i.e., TCR:). Here, we set out to minimize the content of CD3 in TCR:, specific for MAGE-
A1/HLA-A1, without compromising TCR pairing and function. Domain-exchange and 3D-modeling strategies defined a 
set of minimal TCR: variants, which, together with a murinized and cysteine-modified TCR (TCR:mu+cys), were tested 
for functional TCR expression and TCR pairing. Our data with Jurkat T cells show that the CD3 transmembrane domain 
is important for cell-surface expression, whereas the CD3 intracellular domain is crucial for T-cell activation. Notably, 
inability of TCR: to mis-pair was not observed for TCR:mu+cys, which depended exclusively on the transmembrane 
domain of CD3 and could not be recapitulated by a limited number of structurally defined CD3 transmembrane amino 
acids. The extracellular CD3 domain was dispensable for TCR:’s ability to prevent TCR mis-pairing, bind pMHC and 
mediate NFAT activation. In primary human T cells, however, minimal TCR: without CD3’s extracellular domain but 
not TCR: nor TCR:mu+cys revealed compromised cell surface expression and T cell function. Taken together, our study 
demonstrates that CD3’s transmembrane domain dictates TCR:’s inability to TCR mis-pair, but only TCR coupled to 
complete CD3 and not its minimal variants were functionally expressed in primary T cells. 
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INTRODUCTION 
 T cell receptor (TCR) gene therapy is based on retroviral 
transduction of T cells with tumor or virus-specific TCR 
transgenes. Clinical TCR gene therapy trials proved feasible 
and applicable toward multiple tumor types, such as metas-
tatic melanoma, colorectal carcinoma and synovial sarcoma 
[1-4]. This first series of studies with TCR-engineered T 
cells, although showing variable clinical responses in limited 
numbers of patients, demonstrates that responses generally 
lag behind those observed with non gene-engineered T cells 
[5-9]. In addition, in case of TCRs directed against MART-1, 
gp100 or CEA, but not the cancer testis antigen NY-ESO-1, 
treatment resulted in on-target toxicity, i.e., severe inflamma-
tion of healthy tissue expressing the target antigen [1, 2, 4]. 
 The efficacy and safety of clinical TCR gene transfer 
may be further enhanced by strategies that address TCR  
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mis-pairing. TCR mis-pairing is a recognized phenomenon 
of TCR gene transfer, and defined by the incorrect pairing of 
TCR or TCR transgenes with endogenous TCR or TCR 
chains, respectively. TCR mis-pairing leads to the formation 
of unknown TCR specificities, which dilute the surface-
expression of the therapeutic TCR heterodimer and can 
potentially result in off-target toxicity. Although, there is no 
clinical evidence for TCR mis-pairing-induced autoreactiv-
ity, preclinical data derived from a mouse model demonstrate 
that TCR mis-pairing can lead to graft-versus-host disease 
[10]. Strategies that prevent TCR mis-pairing are therefore 
expected to improve T cell avidity by increasing the level of 
cell surface expression of therapeutic TCR heterodimer 
and at the same time reduce potential off-target toxicity, 
reviewed in Govers et al. [11]. These strategies include the 
murinization of TCR and – constant domains [12], intro-
duction of additional cysteine residues in TCR and – to 
form an extra disulfide bridge [13], the exchange of structur-
ally important amino acids between TCR and – [14], or 
the replacement of parts of TCR and – constant domains 
by complete human CD3 (TCR:) [15]. 
 In previous studies, TCR: has been extensively charac-
terized regarding its ability to address TCR mis-pairing and 
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functionally retarget T cells toward several tumor and  
virus antigens, such as MAGE-1/HLA-A1, gp100/HLA-A2, 
BMFL-1/HLA-A2, JC/HLA-A2 and EBNA-4/HLA-A11 
[15-20]. Notably, TCR:’s surface expression, which is  
enhanced when compared to wt TCR, and its ability to form 
immune synapses are independent of endogenous CD3 pro-
teins. This receptor, possibly as a consequence of conforma-
tional changes, results in enlarged synapse sizes in TCR-
transduced T cells [18, 20]. Despite these unique properties, 
TCR: and wt TCR do not differ with respect to the molecu-
lar ‘make-up’ of immune synapses and their ability to medi-
ate antigen-specific T cell functions. 
 In the current study, we set out to minimize the content 
of CD3 present in TCR:, specific for MAGE-A1/HLA-A1, 
without compromising the pairing and functional properties 
of TCR:, and with the intent to potentially decrease the 
immunogenicity of this receptor. In analogy to a study by 
Sommermeyer and colleagues, who defined a limited num-
ber of amino acids that preserved the benefits of murinized 
TCRs [21], the present effort would define those domains or 
amino acids of CD3 responsible for improved TCR pairing 
and function. To generate minimal TCR: variants we ap-
plied a domain-exchange as well as a 3-dimensional (3D) 
modeling strategy, and tested variants for TCR pairing and 
functional expression. We observed that the CD3 trans-
membrane domain, and not a limited number of structurally 
defined amino acids, is critical for TCR:’s surface expres-
sion and its inability to mis-pair with endogenous TCR 
chains, whereas the intracellular CD3 domain is critical for 
T cell activation. A minimal TCR: variant that lacked the 
extracellular CD3 domain was best at preserving both TCR 
pairing and function in Jurkat T cells, but was not function-
ally expressed in primary T cells. 
MATERIALS AND METHODS 
Cells and Reagents 
 Jurkat T cell clone 19 [18], which expresses MelA/HLA-
A2 (MelA) TCR, and EBV-transformed B cell blasts (APD) 
was cultured in RPMI 1640 medium (BioWhittaker, 
Verviers, Belgium) containing 10% Fetal Bovine Serum 
(FBS, Stonehouse, Gloucestershire, UK), streptomycin (100 
μg/ml) and penicillin (100 U/ml) (Jurkat T cell medium). 
The human embryonic kidney cell line 293T, the packaging 
cell line Phoenix-A, and melanoma cell line Mel2A were 
cultured in DMEM medium (BioWhittaker) supplemented 
with 10% FBS, 2 mM L-glutamine, non-essential amino 
acids and antibiotics. T lymphocytes derived from healthy 
donors were isolated and expanded as described elsewhere 
[22] and cultured in HEPES buffered RPMI 1640 medium 
supplemented with 10% Human Serum, 2 mM L-glutamine, 
streptomycin and penicillin. Monoclonal Abs included: 
FITC- and non-conjugated anti-TCR-V19 mAb (Pierce 
Biotechnology, Inc., Rockford, IL); PE- and non-conjugated 
anti-TCR V27 mAb (BD Biosciences, San Jose, USA); PE- 
and non-conjugated anti-TCR-V9 mAb (BD Biosciences 
and Coulter-Immunotech, Marseille, France, respectively); 
PE-conjugated anti-CD107a mAb (BD biosciences); APC-
and non-conjugated anti-CD3 mAb (OKT3) (BD Bio-
sciences and Coulter-Immunotech, respectively); Cy5- and 
non-conjugated Rabbit-anti-Mouse (RM) IgG Fab (Jackson 
ImmunoResearch, Suffolk, UK). Peptide/MHC (pMHC) 
monomers included: MAGE-1 (M1: EADPTGHSY)/HLA-
A*0101; and Melan-A (MelA: ELAGIGILTV)/HLA-
A*0201 biotinylated peptide/MHC monomers (Sanquin, 
Amsterdam, Netherlands), and these pMHC monomers were 
tetramerized as described previously [23]. Other reagents 
included: Retronectin (human fibronectin fragments CH-296, 
Takara Shuzo Co. Ltd., Otsu, Japan); PMA (Sigma-Aldrich, 
St. Louis, USA); PHA (Remel Europe, Dartford, England); 
golgistop (BD biosciences) and streptavidin-PE (BD bio-
sciences). 
Cloning of Minimal TCR: Variants  
 We have generated a panel of 11 TCRs, as schematically 
represented in (Fig. 1), that are specific for MAGE-A1/HLA-
A1 (M1/A1) and have the TCR-V gene usage 
TRAV19/J39/C and TRBV9/D2/J2-3/C2 (with TCR-V(D)J 
gene nomenclature according to http://imgt.cines.fr), origi-
nally derived from CTL clone MZ2-82/30 as described pre-
viously [15]. Control TCRs (n=3) included wt TCR [18], 
TCR: [15, 18] and a murinized plus cysteine-modified TCR 
(i.e., TCR:mu+cys), the latter designed according to Cohen 
and colleagues [24]. TCR:mu+cys was generated via overlap 
PCR to fuse together M1/A1 TCR-V and murine TCR-C 
domains (V-mC and V-mC2), which were ligated in 
pBullet vectors [15] via SalI-XhoI (TCR) and NcoI-XhoI 
(TCR). Cysteine mutations (TCR T189, and TCR S191) 
were generated using QuickChange Site-Directed Mutagene-
sis Kit (Fynnzymes, Espoo, Finland) according to the manu-
facturer’s instructions. The minimal TCR: variants (n=8) 
were generated via either one of the two approaches. First, 
six variants were made using a domain-exchange strategy in 
which extracellular (ec), transmembrane (tm) or intracellular 
(ic) domains of CD3, and combinations of these domains, 
were exchanged for corresponding TCR domains. These six 
variants were named as follows: TCR: ec; TCR: tm; 
TCR: ic; TCR: ec+ic; TCR: tm+ic; and TCR: 
ec+tm ( indicates lack of CD3 domain(s), and replace-
ment by corresponding TCR domain(s)). The exact bounda-
ries of ec, tm and ic domains of CD3, TCR and TCR are 
provided in the legend to (Fig. 1A). These variants were 
generally constructed by overlap PCR and gene synthesis, as 
described in detail in Supplementary Methods. Second, two 
additional TCR: variants were made using a 3D-modeling 
strategy in which a limited number of amino acids of TCR 
tm were exchanged for CD3 tm amino acids at structurally 
favorable positions. These two variants were named as fol-
lows: TCR tm1 and 2, with the exact tm sequences provided 
by (Fig. 1B). The modeling software to design these variants, 
and their construction, generally by gene synthesis, is  
described in detail in Supplementary Methods. All TCR 
constructs made (n=11) were sequence verified (Service XS, 
Leiden, Netherlands). 
Retroviral TCR Gene Transfer into T Cells 
 TCR cDNAs were used to transduce Jurkat T cell clone 
19 as well as human PBMC. To this end, Moloney Murine 
Leukemia retroviruses were produced by a co-culture of the 
packaging cells 293T and Phoenix-A following calcium-
phosphate transfections [16, 18]. Packaging cells were trans-
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fected with TCR cDNAs, pHIT60 MLV GAG/POL, and 
VSV-G envelope plasmids for Jurkat T cell transductions, or 
with TCR cDNAs, pHIT60 MLV GAG/POL, and pCOLT-
GALV-envelope encoding plasmids for human PBMC trans-
ductions. The transduction procedure used was optimized for 
human T cells and described previously [25]. 
Flow Cytometry and FACsort  
 TCR-transduced T cells (1x10
4
 cells) were monitored by 
flow cytometry for surface expression of transgenic TCR 
using FITC-conjugated anti-TCR-V19, PE-conjugated anti-
TCR-V9 mAbs and/or R-PE-conjugated M1/A1 tetramer; 
endogenous TCR (in case of Jurkat T cells) using PE-
conjugated anti-TCR-V27 mAb and/or R-PE-conjugated 
MelanA/A2 tetramer; and endogenous CD3 using APC-
conjugated anti-CD3 mAb. After T cells were washed, they 
were incubated with mAbs for 30 min on ice, or 15 min at 
RT for pMHC tetramers. Next, T cells were washed and 
fixed with 1% PFA (Brunschwig, Amsterdam, the Nether-
lands) before measurements on a FACSCalibur dual-laser 
flow cytometer (Beckton Dickinson, Alphen a/d Rijn, the 
Netherlands). Samples were analyzed using BD Cellquest 
software and displayed as dotplots or histograms. Enrich-
ment of M1/A1 TCR-expressing Jurkat Clone 19 T cells was 
performed by two-color Fluorescent Activated Cell Sorting 
(FACS) following staining with FITC conjugated anti-TCR-
V19 and PE conjugated anti-TCR-V9 mAbs.  
Flow Cytometry-Based FRET 
 PE-labeled mAbs were used as donor and Cy5-labeled 
RM antibody as acceptor and used in the following do-
nor/acceptor combinations (as described in [18]): anti-TCR-
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
Fig. (1). Scheme of minimal TCR: variants. (A) Minimal TCR: constructs were modified via replacement of either extracellular (ec), 
transmembrane (tm), intracellular (ic), extra and intracellular (ec+ic), transmembrane and intracellular (tm+ic) or extracellular and 
transmembrane CD3 domains (ec+tm) (black) by corresponding TCR and TCR domains (white). Boundaries for the CD3/TCR ec, 
tm and ic domains were defined as follows. CD3 (genbank accession number: CAI21380.1) ec, tm and ic: nt 73-90 (aa 25-30); nt 91-153 (aa 
31-51); and nt 154-489 (aa 52-163). TCR [48] ec, tm and ic: nt 703-765 (aa 235-255); nt 766-825 (aa 256-275); and nt 826-840 (aa 276-
280). TCR [48] ec, tm and ic: nt 790-846 (aa 264-282); nt 847-912 (aa 283-304); and nt 913-933 (aa 305-311). In addition, two minimal 
TCR: constructs were designed in which defined amino acids of tm CD3 were transplanted onto structurally favourable positions in TCR 
and TCR tm domains, and were termed minimal TCR:tm1 and 2 (See Fig. (1B)). Control TCRs include: wt TCR, TCR: and a TCR con-
taining murine constant domains and additional cysteines (TCR:mu+cys, as described in [24]). (B) Transmembrane amino acids of CD3 and 
minimal TCR: variants TCR:tm1, TCR:tm2, and TCR:tm (CD3 amino acids underlined). 
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Vb27
PE
 + anti-TCR-V19/ GMCy5 and anti-TCR-Vb9PE + 
anti-CD3 (OKT3)/GMCy5. Staining was performed sequen-
tially, with extensive washing steps in between, using the 
following order of staining steps: first non-conjugated mAbs, 
second Cy5-labeled Abs, and last PE-labeled donor Abs. 
Fluorescence intensities of emissions at 570 nm (donor 
channel, excitation at 488nm), 670 nm (acceptor channel, 
excitation at 635), and over 670 (FRET channel, excitation at 
488 nm) were measured and collected on a FACSCalibur. 
Data were analyzed with the FLEX software on a per-cell 
basis [26]. 
NFAT Reporter Gene Assay 
 Gaussia-Luciferase reporter gene under the control of 6 
NFAT response elements, a minimal IL-2 promotor, and a 
TATA box (in short: GLuc-NFAT(RE)6) was used to quan-
tify TCR-mediated stimulation. Gluc-NFAT(RE)6 was gen-
erated by digesting a plasmid containing NFAT-6-luc [27] 
with NcoI-HinDIII and ligating this fragment (containing the 
6 NFAT response elements, minimal IL-2 promotor and 
TATA box), together with a EcoRI-NcoI linker, in EcoRI-
HinDIII digested pGluc-basic vector (New England Biolabs, 
Ipswich, USA). 5x10
6
 Jurkat TCR-transduced T cells were 
transiently nucleofected with an Amaxa nucleofector 
(AmaxaBiosystems, Cologne, Germany) according to previ-
ous optimizations [28, 29]. Briefly, T cells were resuspended 
in 100 μl supplemented buffer V to which 5 μg GLuc-
NFAT(RE)6 was added and pulsed with the Nucleofector set 
at program C-16. Next, T cells were immediately transferred 
to 2.5 ml warm Jurkat T-cell medium in T25 flasks for O/N 
recovery at 37°C and 5% CO2. Non-tissue culture-treated 96-
well plates were coated with non-conjugated mIg Ab, anti-
TCR-V9 mAb (100 ng) or biotinylated M1/A1 or JC/A2 
monomers (titrated from 126 nM down to 4 nM). The latter 
added to streptavidin-coated plates O/N at 4°C. Twenty 
hours post-transfection, 0.2x10
6
 T cells at a concentration of 
1x10
6
/ml were transferred to each well in the 96-well plates 
and stimulated for 6 hours at 37°C and 5% CO2. Subse-
quently, 25 μl supernatant was transferred to 96 wellplate 
read-out plates (Corning incorporated, Costar assay plate, 
Lowell, USA) and placed in a luminometer. Next, 50 μl 
assay buffer was added (Gluc substrate; New England Bio-
labs, Ipswich, USA). Light units indicative of the Gaussia 
Luciferase-mediated enzymatic transition of coelenterazine 
into coelenteramide were measured according to the manu-
facturer’s instructions (Mediators, Vienna, Austria) and 
expressed (in RLU) relative to wt TCR luciferase activities 
(100% for each concentration) 
CD107a Mobilization Assay 
 TCR-transduced human PBMC (1x10
6
) were resus-
pended in 0.15 ml T cell medium, 0.5 μl Golgistop (BD 
biosciences), and 100 μl anti-CD107a-PE (BD biosciences). 
Mel2A and APD target cells (1x10
6
) were resuspended in 
0.25 ml T cell medium (± 10 μM M1 peptide). Next, 50 μl 
target cells and 50 μl T cells were mixed in a tissue culture 
treated 96-well plates (Greiner bio-one) and incubated for 2 
h at 37°C and 5% CO2. After the cells were washed, they 
were stained with anti-V19-FITC and anti-CD3-APC for 
30 minutes at 4°C in the dark. Next, cells were washed and 
fixed with 1% PFA and measured on a FACS Calibur dual-
laser flow cytometer. T cells gated for viability (FSC and 
SSC) and positive for CD3 and TCR-V19, were assessed 
for surface expression of CD107a. 
Statistical Analyses 
 Differences among TCRs in various assays were tested 
with student’s t-tests (unpaired; two-tailed) using Graphpad 
Prism 4 software. Differences with p values <0.05 were 
considered significant. 
RESULTS 
CD3 Transmembrane Domain is Required for Surface 
Expression of TCR: 
 Jurkat T cells containing MelA/A2 TCR were used as 
recipient cells for a panel of 6 M1/A1 minimal TCR:’s, 
each incorporating a different but minimal of ec, tm and/or ic 
CD3 domains (see Fig. (1) for details). These dual-TCR 
Jurkat T cells were assessed for surface expression of trans-
genic TCR by flow-cytometry. Minimal TCR: ec, ic, 
ec+ic, all containing the CD3 tm domain, revealed a sur-
face expression pattern like that of parental TCR: with a 
typical diagonal, high mean fluorescence intensity (MFI) and 
absence of single TCR-chain positive cells (see Fig. (2A); 
[18]). TCR: ic and ec+ic revealed lower levels of surface 
expression than TCR: ec or TCR:. In contrast, TCR: 
tm, tm+ic and ec+tm transduced Jurkat T cells showed 
no surface expression of either or both TCR: and TCR: 
chains (Fig. 2A). Further analysis of these latter TCRs re-
vealed that mRNA, but not intracellular proteins were con-
sistently present, suggesting that not gene transcription but 
more likely protein translation and/or transportation to the 
cell surface were hampered (Supplementary Fig. 1). Notably, 
the TCR:mu+cys, a murinized and cysteine-modified TCR 
used as a control TCR, shows an extended diagonal surface 
expression pattern and no or less single TCR-chain positive 
T cells than wt TCR, similar to TCR: or its CD3  
tm-containing variants (Fig. 2A) and suggestive for high 
preferential TCR pairing. 
CD3 Transmembrane Domain Critically Determines the 
Inability of TCR: to Associate With Endogenous CD3 
and TCR Chains 
 The minimal TCR: variants were assessed for their in-
ability to associate with endogenous CD3, considered a 
unique characteristic of TCR:, using conventional flow 
cytometry and flow cytometric Fluorescence Resonance 
Energy Transfer (FRET). Flow cytometry analyses after 
double-staining for TCR and CD3 revealed diagonal dot-
plots in Jurkat T cells expressing wt TCR and TCR:mu+cys, 
but not TCR: or any of its minimal TCR variants (Fig. 3A). 
These data suggest on one hand a CD3-independence of 
minimal TCR: variants that contain CD3 tm, similar to the 
reported CD3-independence of TCR:, and confirm on the 
other hand a CD3-dependence of wt TCR and TCR:mu+cys 
[11]. The lack of competition for CD3-proteins by TCR: 
ec, ic, ec+ic was also reflected in the expression of en-
dogenous TCR. TCR: or these variants did not alter the MFI 
of endogenous TCR, whereas wt TCR or TCR:mu+cys 
approximately halved the MFI of endogenous TCR (data 
not shown). Subsequent studies focused only on the three 
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minimal TCR: variants that were expressed on the cell sur-
face. Flow cytometric FRET confirmed lack of association 
between TCR: or its minimal variants, but not wt TCR or 
TCR:mu+cys, and CD3 (Fig. 3B). Flow cytometric FRET 
was also applied to address the extent TCRs were prone to 
TCR mis-pairing. Using antibodies specific for endogenous 
TCR-V27 (PE-fluorochrome, donor) and the TCR-V19-
transgene (Cy5-fluorochrome, acceptor), we observed no 
FRET signals above background for TCR: ec, ic, or 
ec+ic variants, similar to parental TCR:, indicating that  
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
C 
 
 
 
 
 
Fig. (2). Minimal TCR: ec, ic and ec+ic express at T cell surface. Jurkat T cells expressing MelA/A2 TCR (Jurkat cl. 19) were trans-
duced with one of the following M1/A1 TCRs: minimal TCR: ec, tm, ic, ec+ic, tm+ic, ec+tm, TCR tm 1, tm 2, TCR:, wt TCR, 
TCR:mu+cys, or no TCR transgene. (A) Surface expression levels of transgenic MA1/A1 TCRs were measured via flow cytometry using 
anti-TCR-V19FITC and anti-TCR-V9PE mAbs. Representative dotplots out of 5 individual measurements are displayed. See Supplementary 
Fig. 1. for extended analysis of intracellular protein and mRNA expression of those minimal TCR: variants that did not show surface ex-
pression of both TCR-V19 and TCR-V9, i.e., minimal TCR: tm, ec+tm, tm+ic, TCR:tm 1 and tm 2. (B) TCR surface expression of 
Jurkat T cell lines transduced with minimal TCR: ec, ic and ec+ic or controls wt TCR, TCR: and TCR:mu+cys after FACSort with 
anti-TCR-V19FITC and anti-TCR-V9PE mAbs. Representative dotplots out of 5 individual measurements are displayed and percentages of 
stained T cells in upper left and upper right quadrants are indicated. (C) Mean Fluorescence Intensities or percentages (both + SEM) of 
TCR in upper right quadrants in (B), n=6-11 independent measurements (statistically significant differences in comparison to wt TCR are 
calculated with student’s t-tests; p-values indicated in Fig). 
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these variants preserve TCR:’s ability to successfully  
address TCR mis-pairing (Fig. 3C). Notably, when using a 
sensitive methodology such as FRET, TCR:mu+cys TCR 
are mis-paired with endogenous TCR to the same extent as 
wt TCR. Additional proof for the absence or presence of 
TCR mis-pairing came from single TCR chain transductions 
of Jurkat T cells. Supplementary Fig. 2 demonstrates signifi-
cant cell surface expression of a TCR heterodimer (indica-
tive of TCR mis-pairing) upon transduction with single chains 
(either TCR or -) of wt TCR or TCR:mu+cys, but not 
minimal TCR: variants or TCR:. 
 Next, we attempted to identify a limited number of CD3 
tm amino acids important for TCR:’s surface expression 
and inability to mis-pair. A 3D-modeling strategy was ap-
plied to define a set of CD3 transmembranal amino acids 
that was subsequently transplanted onto favorable positions 
in the transmembrane domain of TCR chains. This resulted 
in TCR: variants tm1 and -tm2 which were retrovirally 
introduced in Jurkat T cells. Flow cytometry revealed no cell 
surface expression of minimal TCR:tm1 or -2 heterodimers 
on these dual-TCR Jurkat T cells (Fig. 2A). TCR:tm1  
and -2 chains were not able to complex with TCR:tm or 
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B        C 
 
 
 
 
 
 
 
 
 
Fig. (3). Minimal TCR: ec, ic and ec+ic show neither CD3 association nor TCR mis-pairing. (A) Jurkat T cells expressing minimal 
TCR: ec, ic and ec+ic, TCR:, wt TCR, TCR:mu+cys transgenes were tested for surface expression of transgenic TCR and CD3 via 
flow cytometry using anti-TCR-V1PE and anti-CD3APC antibodies. Representative examples out of 5 individual measurements are dis-
played. (B) CD3 association and (C) TCR mis-pairing were determined of minimal TCR: ec, ic and ec+ic and control TCRs using 
Fluorescence Resonance Energy Transfer (FRET) between anti-V9PE->anti-CD3-RMCy5 and anti-V27PE->anti-V19-RMCy5 mAbs, 
respectively. Please note that FRET was measured using TCR-transduced but non-sorted Jurkat T cells after gating on M1/A1-specific TCR 
expressing cells. Dotted line represents the level of background signal (5%) and bars represent mean FRET values + SEM, n=4 independent 
measurements (statistically significant differences in comparison to wt TCR are calculated with student’s t-tests; * = p<0.05; ** = p<0.005). 
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endogenous TCR. Also, TCR:tm showed moderate levels 
of surface expression through mis-pairing with the endogenous 
TCR. Analysis of mRNA and intracellular protein sug-
gested difficulties in protein transportation to the cell surface 
of particularly both TCR-chains (Supplementary Fig. 1). 
Thus, we were unable to attribute strong CD3-independent 
cell surface expression and prevention of TCR mis-pairing to 
a subset of CD3 transmembranal amino acids.  
Minimal TCR: ec Performs best at Preserving the 
Ability of TCR: to Bind pMHC and Activate NFAT 
 To study TCR-mediated functions, we have FACSorted 
Jurkat TCR-transductants with TCR and - mAbs to en-
hance and equalize surface expression levels of the different 
TCR formats (Fig. 2B). Enrichment resulted in similar sur-
face expression levels of TCRs (range between 74 - 92%), 
except for TCR: ec+ic which fell behind (48%) (Fig. 2C). 
MFIs were within the same range for TCR: ec, ic and 
parental TCR: (TCR: ec: 163 and 1145; TCR: ic: 133 
and 998; and TCR:: 242 and 1646 for TCR and - chains, 
respectively), and were lowered for TCR: ec+ic (76 and 
578) (Fig. 2C). In fact, MFIs of TCR: ec+ic were within 
the same range as those for wt TCR and TCR:mu+cys (wt 
TCR: 64 and 633; TCR:mu+cys: 66 and 540). Please note 
that levels of surface expression of TCR: and its variants do 
not take into account TCR stainings in upper left quadrants 
of flow cytometry dot plots. Since these stainings extend the 
diagonal of flow cytometry dotplots and are not due to TCR 
mis-pairing (Fig. 3C), levels of surface expression, as put in 
Fig. 2C, may underestimate total surface expression levels of 
TCR: and its variants. 
 Subsequently, transgenic TCRs were standardized for 
average cell surface expression levels (with % surface ex-
pression of wt TCR (see (Fig. 2C)) set to 1.0) and compared 
for their ability to recognize and bind pMHC. The TCR: 
ec transgene revealed a slightly lower percentage of pMHC 
binding compared to the TCR: transgene, detected at all 
measured concentrations, although differences reached no 
statistical significance (Fig. 4A). Wild-type TCR, TCR:mu+cys, 
and TCR: transduced Jurkat T cells showed the highest 
percentages of pMHC positive populations (Fig. 4A). Again, 
when analyzing the MFIs of pMHC binding, we noted that 
Jurkat T cells expressing TCR: ec or parental TCR: were 
the two T cell lines with the highest TCR expression levels 
(Figs. 4B and 2C). Although TCR: ec shows a pMHC 
binding approximately half of that of parental TCR:, both 
show a significantly increased MFI compared to wt TCR 
(TCR: vs wt TCR: p<0.05 at all concentrations; and TCR: 
ec vs wt TCR: p<0.05 at 4 out of 6 concentrations). TCR: 
ic and ec+ic variants showed a negligible pMHC binding, 
whereas TCR:mu+cys showed a pMHC binding that was 
slightly lower than wt TCR. 
 Next, we measured antigen-specific T cell activation by 
employing a Gaussia Luciferase reporter assay based on six 
response elements of Nuclear Factor of Activated T cells 
(NFAT), a transcription factor that is a key step in T cell 
activation. With transgenic TCRs being standardized for 
average cell surface expression levels (Fig. 2C), we observed 
that TCR: ec and parental TCR: proved to be most potent 
in activating Jurkat T cells by inducing the highest level of 
luminescence, which was significantly higher when com-
pared to wt TCR (Fig. 5). TCR: ic and ec+ic variants, 
however, did not mediate T cell activation, even though 
these TCRs were able to bind pMHC. To further investigate 
the potency of TCR: ic and ec+ic to induce intracellular 
T cell signaling, we stimulated Jurkat T cells with anti-TCR-
V9 mAbs and demonstrated that these two TCRs, both 
lacking the intracellular CD3 immunoreceptor tyrosine-
A                  B 
 
 
 
 
 
 
 
 
 
Fig. (4). T cells transduced with minimal TCR: ec, ic or ec+ic show decreased ability to bind pMHC, which is least compro-
mised for TCR: ec. Jurkat T cells expressing minimal TCR: ec, ic and ec+ic, TCR:, wt TCR, TCR:mu+cys transgenes or no TCR 
transgene were tested for their ability to bind M1/A1 tetramer PE complexes. The amount of M1/A1-tetramer used to stain 0.5 x 10
6
 cells (30 
min, RT) was titrated from 112 nM down to 3.5 nM. Percentages (A) and MFIs (B) of pMHC binding by T cells were measured via flow 
cytometry. Percentages of pMHC binding were standardized for average cell surface expression levels (with % surface expression of wt TCR 
(see Fig. (2C)), set to 1.0). Curves represent mean percentages of MFI or pMHC binding + SEM, n=4 independent measurements (statisti-
cally significant differences in comparison to wt TCR are calculated with student’s t-tests; * = p<0.05; ** = p<0.005). 
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based activation motifs (ITAMs), were not able to mediate T 
cell activation (Supplementary Fig. 3). Stimulations of the 
endogenous TCR with anti-TCR-V27 mAb did not show 
reduced NFAT activation upon transduction with TCR: ec, 
ic or ec+ic, in line with parental TCR: [18] (data not 
shown). In contrast, stimulation with anti-TCR-V27 mAb 
did show significantly reduced NFAT activation upon trans-
duction with wt TCR or TCR:mu+cys, a result of down-
regulated surface expression of CD3-dependent TCRs in 
dual TCR T cells.  
Minimal TCR: ec Shows a Compromised Surface  
Expression and Function in Primary Human T Cells 
 The next step was to test the minimal TCR: variant that 
performed best in Jurkat T cells with respect to surface ex-
pression, absence of TCR mis-pairing, pMHC binding and 
activation of NFAT, i.e., TCR: ec, in primary human T 
cells. Anti-CD3 mAb-activated human PBMC were retrovi-
rally transduced with TCR: ec, TCR:, wt TCR and 
TCR:mu+cys. To enhance the functional expression of 
TCR: ec, we codon optimized CD3 ec and aligned the 
two chains in a TCR-2A-TCR configuration in a pMP71 
retroviral vector [30-33]. Surface expression of TCR trans-
genes and pMHC binding were assessed by flow-cytometry 
in cultures of TCR-engineered T cells (> 90 % CD8-positive 
T cells). Please note that, for reasons explained above, per-
centages of surface expression displayed in the upper right 
quadrants of flow cytometry dotplots may provide an under-
estimation of the actual levels of surface expression of 
TCR: and TCR: ec (with and without codon optimiza-
tion) (Fig. 6A). TCR: ec revealed a weak surface expres-
sion and pMHC binding, which was, unexpectedly, not im-
proved when using TCR:opt. ec in a -2A- configuration 
in pMP71 (Figs. 6A,B). Notably, the surface expression 
levels of TCR: and TCR:mu+cys were higher when com-
pared to wt TCR (Fig. 6A). However, when looking at the 
pMHC binding, only TCR:, and not TCR:mu+cys, demon-
strated enhanced performance when compared to wt TCR 
(Fig. 6B).  
 Finally, primary human T cells expressing TCR trans-
genes were stimulated with antigen-positive and negative 
target cells, after which CD107a mobilization on the cell 
surface was measured within the TCR-V19 positive T cell 
population as a measure for cytotoxicity. TCR: ec, 
whether or not with codon optimized CD3 and in an  
optimal vector cassette, mediated negligible antigen-specific  
responses in contrast to TCR: (p<0.005, Fig. 6C). Both 
TCR: and TCR:mu+cys show a higher percentage of 
CD107a positive cells than T cells with wt TCR transgenes. 
DISCUSSION 
 In this study, we generated novel MAGE-A1-specific 
TCRs fused to partial rather than complete human CD3 in 
an effort to identify a minimal TCR: that preserved the TCR 
pairing and functional properties of TCR:. To this end, a 
panel of 8 minimal TCR:’s (see Fig. (1) for details) was 
tested for surface expression, association with endogenous 
CD3 and TCR chains, pMHC binding and TCR transgene-
mediated functions in Jurkat T cells and primary human T 
cells. Our observations revealed that for TCR: and its vari-
ants: (a) intact CD3 transmembrane (tm) domain critically 
determines surface expression and inability to associate with 
endogenous CD3 and TCR chains in Jurkat T cells; (b) both 
CD3 extracellular (ec) and intracellular (ic) domains are 
dispensable for pMHC binding, whereas only CD3 ec do-
main is dispensable for T cell mediated signaling in Jurkat T 
cells; and (c) the combination of CD3 ec, tm and ic domains 
is required for surface expression and T cell function in pri-
mary human T cells. 
 
 
 
 
 
 
 
 
Fig. (5). T cells transduced with minimal TCR: ec show a potent antigen-specific NFAT response. Jurkat T cells expressing minimal 
TCR: ec, ic and ec+ic, TCR:, wt TCR, TCR:mu+cys transgenes or no TCR transgene were tested for their ability to mediate activation 
of Nuclear Factor of Activated T cells (NFAT). TCR-transduced Jurkat T cells were nucleofected with a Gaussia Luciferase reporter con-
struct under control of 6 NFAT response elements, and stimulated for 6h with pMHC monomers. The concentration of monomers was ti-
trated from 126 nM down to 4 nM. Luciferase activities of wt TCR T cells for 4, 8, 16, 32, 63, and 126 nM pMHC were: 588926, 670147, 
656821, 444174, 181790, and 37084 relative luminescence units (RLU), respectively, and were all set at 100% (dotted line). Luciferase 
activities of TCR-transduced T cells were standardized for average cell surface expression levels (as explained in legend to Fig. 4A). Curves 
represent mean luminescence units + SEM, n=6-14 independent measurements (statistically significant differences in comparison to wt TCR 
are calculated with student’s t-tests; * = p<0.05, *** = p<0.0005). 
TCR Fused to Minimal Domains of CD3 The Open Gene Therapy Journal, 2011, Volume 4    19 
  
A 
 
 
 
 
 
B 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
Fig. (6). Minimal TCR: ec demonstrates compromised surface expression and antigen-specific function in primary human T cells. 
Primary human T cells were transduced with one of the following M1/A1 TCRs: TCR: ec, pMP71 -2A- TCR:opt. ec, TCR:, wt 
TCR, TCR:mu+cys, or no TCR. (A) Surface expression of transgenic TCR was measured via flow cytometry. Anti-TCR-V19FITC and anti-
TCR-V9PE antibodies were used to stain TCR-transduced T cells. Representative examples out of 5 individual measurements of two healthy 
donors are displayed and percentages of stained T cells in upper left and upper right quadrants are indicated. Percentages indicated in italics 
are either percentages of upper right quadrants (wt TCR, TCR:mu+cys) or the sum of percentages of upper left and upper right quadrants 
(TCR:, TCR: ec, TCR:opt. ec), corrected for the corresponding percentage(s) of Mock T cells. These percentages (in italics) may better 
represent the actual levels of surface expression of TCR: and its variants (see Result section for details). (B) pMHC binding by transgenic 
TCR was measured via flow cytometry. M1/A1-tetramer-PE complexes (15 nM) were used to stain TCR-transduced T cells, and percentages 
of positive cells in histograms are indicated. Representative examples out of 5 individual measurements of two healthy donors are displayed 
and percentages of stained T cells in selected histogram region are indicated (in italics: corrected for pMHC binding observed by Mock T 
cells). (C) CD107a-mobilization to cell surface of TCR-transduced T cells. TCR-transduced T cells were stimulation for 2h with medium, 
Mel2A or APD (both M1 negative, HLA-A1 positive), or Mel2A and APD loaded with 10 μM M1 peptide, after which T cells were analyzed 
for CD107a expression by flow cytometry (see Materials and Methods section for details). Bars represent mean CD107a values + SEM, 2 
independent measurements of two healthy donors (statistically significant differences are calculated with student’s t-tests; ** = p<0.005). 
Please note that at the time of flow cytometry analyses, TCR-engineered primary human T cells contained > 90 % CD8-positive T cells. 
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 In the first series of experiments, we have analyzed 6 
minimal TCR: variants, in which the ec, tm and/or ic do-
main(s) of CD3 were omitted (and replaced by correspond-
ing TCR domain(s)). Cell surface expression analysis re-
vealed that not all minimal TCR: variants resulted in detec-
tion of a M1/A1 TCR heterodimer. In case the CD3 tm 
domain was absent (i.e., TCR: tm, tm+ic, ec+tm), 
TCR: and -: transgenes were not properly expressed as a 
TCR heterodimer (Fig. 2A). In fact, TCR chains of these 
minimal TCR: variants showed aberrant protein expression 
or transport to the cell surface (Supplementary Figs. 1B, C). 
TCR: and its variants that were expressed (i.e., TCR: ec, 
ic, and ec+ic,), show similarly strong levels of cell surface 
expression (TCR: ec+ic to a lesser extent; Fig. 2) and an 
inability to associate with CD3 (Fig. 3A, B). Functional 
assays, however, identified two groups of TCRs: (1) TCR: 
and TCR: ec; and (2) TCR: ic and TCR: ec+ic. The 
latter group of TCRs, in contrast to the first group, revealed 
lowered to negligible binding of pMHC (Figs. 4A, B) and an 
inability to induce NFAT activity upon stimulation with 
either pMHC (Fig. 5) or anti-TCR-V9 mAb (Supplemen-
tary Fig. 3). Our finding that TCR: variants that lack the 
CD3 ic domain showed compromised pMHC binding is 
unexpected. Studies with other antigen-specific receptors 
argue that lack of, or not having access to, ITAM-bearing 
CD3 ic domain results in enhanced surface expression and 
pMHC binding. For example, inhibition of protein tyrosine 
kinases demonstrated that early TCR-mediated signaling 
normally provides a negative feedback loop that facilitates 
pMHC-induced TCR down-regulation and T cell apoptosis 
[34, 35]. Moreover, studies with Chimeric Antibody Recep-
tors coupled to CD3 (i.e., CAR:) showed that CD3 
ITAMs directly contribute to loss of transgene expression 
and enhanced sensitivity to apoptosis [36]. In contrast, 
TCR: is different from other receptors since it does not 
dimerize with endogenous TCR/CD3 complexes [18] and 
may signal differently [37]. Moreover, recent studies into 
immune synapses suggested that TCR: has a distinct con-
formation [20], and we propose that conformational changes 
due to extensive deletions, such as ic and ec+ic, cause the 
observed decrease in pMHC binding. The observation that 
TCR: ic and ec+ic can not mediate activation of NFAT, 
even upon stimulation with anti-TCR mAb, points out that 
TCR-mediated signaling either requires a modified TCR that 
contains ITAMs (i.e., TCR: or minimal TCR: ec) or a 
(modified or wt) TCR that is able to recruit endogenous and 
ITAM-containing CD3 molecules.  
 In addition to the shared inability to associate with CD3, 
minimal TCR: ec, ic, and ec+ic and the parental TCR:, all 
containing an intact CD3 tm domain, showed no association 
with endogenous TCR chains (Fig. 3C and Supplementary 
Fig. 2). Notably, flow cytometry of TCR: tm+ic and 
TCR: ec+tm showed cells that were single positive for 
either TCR-V19 or -V9, respectively (Fig. 2A), indicating 
that CD3 ec or ic domains do not completely prevent these 
TCRs from mis-pairing. Our finding that prevention of TCR 
mis-pairing, and consequently enhanced pairing between 
TCR: and -:, is governed by the CD3 tm domain is 
consistent with a report by Rutledge and colleagues [38], in 
which the CD3 tm domain was used to induce dimerization 
of monomeric proteins, such as the IL-2R chain. 
 In the next series of experiments, we have transplanted a 
limited set of CD3 tm amino acids onto TCR and TCR 
with the intent to preserve surface expression and inability to 
TCR mis-pair and, at the same time, retain structural and 
spatial requirements to associate with endogenous CD3 
chains (i.e., TCR:tm1 and -2, (see Fig. 1)). This ‘transplan-
tation set’ of amino acids was identified through 3D model-
ing and included the ones defined by Call and colleagues to 
be critically involved in CD3 homodimerization (i.e., C2, 
D6, L9, Y12, T17 and F20) [39]. We observed that TCR:tm 
heterodimers did not express at the cell surface (Fig. 2A). In 
fact, TCR:tm1 and -2 chains were not able to complex 
with TCR:tm nor endogenous TCR, and TCR:tm 
showed moderate levels of surface expression through mis-
pairing with the endogenous TCR. These data suggest that 
TCR: properties related to the presence of an intact CD3 
tm domain, such as enhanced cell surface expression and 
inability to associate with endogenous CD3 and TCR chains, 
cannot be attributed to a limited number of individual CD3 
tm amino acids. 
 TCR:’s pairing and functional properties were best pre-
served in minimal TCR: ec. This TCR variant retains high 
surface expression levels (Fig. 2), prevents pairing with 
endogenous CD3 and TCR chains (Fig. 3), binds pMHC 
(although binding is somewhat reduced when compared to 
TCR:, (Fig. 4), and potently activates NFAT (Fig. 5). Inter-
estingly, recent confocal microscopy studies demonstrated 
that minimal TCR: ec is able to form immunological syn-
apses with similar sizes as those formed by parental TCR: 
[20]. In minimal TCR: ec there is only a single artificial 
boundary, i.e., the one between TCR ec and CD3 tm se-
quences, potentially preventing or diminishing humoral 
and/or cellular immunogenicity. Collectively, our observa-
tions warranted testing of minimal TCR: ec in primary 
human T cells. In bulk populations of human PBMC (non-
sorted for either TCR or CD8 expression), we observed that 
the difference in surface expression between minimal TCR: 
ec and parental TCR: was more pronounced when com-
pared to Jurkat T cells (Fig. 6A). Also, minimal TCR: ec 
showed lower pMHC binding and induced negligible 
CD107a mobilization to the cell surface when compared to 
TCR: (Figs. 6B, C), which most likely was accounted for 
by the low level of surface expression. These observations, 
perhaps unexpectedly, were not different when using mini-
mal TCR: ec in an optimal vector, an optimal TCR cas-
sette and with codon optimized CD3 tm+ic domains. Ap-
parently, the absence of the membrane-proximal CD3 ec 
domain in minimal TCR: ec results in a stringent decrease 
in functional TCR expression. Interestingly, single chain (sc) 
Fv [40] and scTCR ([15], and data not shown) that do con-
tain CD3 ec coupled to either CD3 tm+ic, CD4 tm + 
Fc()RI ic, or Fc()RI tm+ic, have indeed demonstrated 
significant surface expression in human T cells. In minimal 
TCR: ec, six CD3 ec amino acids (GDLDPK) were re-
placed by either TCR (DVKLVEKSFETDTNLNFQNLS) 
or TCR (GFTSESYQQGVLSATILYE) ec amino acids 
(that cover the connecting-peptide motifs CPM and CPM, 
respectively). The CPM and CPM are reported to interact 
with tetracysteine motifs in the membrane-proximal stalk 
regions of CD3 and CD3 dimers, and as such contribute 
to TCR/CD3 complex formation and T cell activation [41, 
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42]. In addition, a defective or mutated CPM is compro-
mised with respect to its association with CD8, translation of 
antigen-specific stimulation into phosphorylation of Lck, 
Fyn, and ZAP70, and production of IL-2 [41, 43, 44]. We 
observed that the presence of CPM and - in minimal 
TCR: ec appears not sufficient to induce TCR/CD3 com-
plex formation (Figs. 3A, B), suggesting a more critical role 
for intact TCR tm for association with CD3 chains [45]. The 
extent to which the presence of CPM and - in minimal 
TCR: ec improved pMHC binding in T cells is difficult to 
assess due to poor expression levels in primary human T 
cells (Fig. 6A) and non-specificity of pMHC binding in 
CD8-transduced Jurkat T cells (data not shown). Neverthe-
less, earlier findings proved that M1/A1-specific TCR:, not 
containing CPM or –, were able to associate with and 
depend on CD8 for ligand binding [20, 46], and may sug-
gest a non-dominant role of CPM with respect to TCR:CD8 
association. 
 An alternative TCR format that is designed to address 
TCR mis-pairing, in addition to TCR:, is TCR:mu+cys. In 
TCR:mu+cys two separate strategies have been combined: 
murinization of the TCR-C domain and introduction of cys-
teine amino acids at structurally favorable positions to allow 
formation of an additional disulfide bridge, which together 
result in enhanced functional expression [24, 47] (reviewed 
in [11]). Our studies with M1/A1-specific TCR:mu+cys, 
taken along as a control TCR in the present paper, confirmed 
this notion to some extent. In Jurkat T cells, TCR:mu+cys, 
when compared to wt TCR, showed similar levels of surface 
expression and pMHC binding, and somewhat enhanced 
levels of antigen-specific NFAT activation (Figs. 2A, 4 and 
5), whereas in primary human T cells, TCR:mu+cys showed 
enhanced levels of surface expression and similar levels  
of pMHC binding and antigen-specific CD107a mobilization 
to the cell surface (Fig. 6). However, we did observe that 
TCR:mu+cys mediates a significantly enhanced antigen-
specific IFN response (data not shown). These findings, 
although not fully in accordance with previous reports and 
potentially unique to the TCR-V regions of the M1/A1 TCR 
[24, 47], generally argue that TCR:mu+cys improved func-
tional TCR expression. Expectedly, enhanced functional 
TCR expression was related to enhanced preferential pairing 
between the two modified TCR:mu+cys chains, which was 
suggested by the flow cytometric absence of single TCR or 
TCR positive cells (Fig. 2A). Unexpectedly, however, flow 
cytometric FRET (Fig. 3B) and single TCR chain transduc-
tions (Supplementary Fig. 2) clearly demonstrated that 
TCR:mu+cys mis-paired with endogenous TCR chains to the 
same extent as wt TCR. Also in vivo, murine TCRs with a 
cysteine modification did not fully prevent the pathology 
related to TCR mis-pairing, i.e., TCR transfer-induced Graft 
versus Host disease [10]. We therefore propose that from a 
safety point of view, TCR: but not TCR:mu+cys provides a 
better alternative to wt TCR.  
 In conclusion, our studies showed that CD3 domains 
separate various properties of TCR:, i.e., the CD3 tm do-
main determines surface expression and lack of association 
with endogenous CD3 and TCR chains, whereas CD3 ic 
domain contributes to T cell signaling. Functional expression 
of TCR: in primary human T cells, however, required the 
complete rather than minimized content of CD3. 
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